Table 1 Major cancer immunotherapeutics approved by the US Food and Drug Administration (FDA)
From: New opportunities for nanoparticles in cancer immunotherapy
|
Drug (Trade Name) |
Drug Type (Target) | Targeted Cancer |
FDA Approval Date |
|---|---|---|---|
|
Ipilimumab (Yervoy®) |
Monoclonal antibody (CTLA-4) | Advanced melanoma | March 2011 |
|
Pembrolizumab (Keytruda®) |
Monoclonal antibody (PD-1) | Advanced refractory melanoma and non–small cell lung cancer | September 2014 |
|
Nivolumab (Opdivo®) |
Monoclonal antibody (PD-1) | Unresectable or metastatic melanoma squamous non–small cell lung cancer | December 2014 |
|
Atezolizumab (Tecentriq®) |
Monoclonal antibody (PD-L1) | Locally advanced or metastatic bladder cancer | May 2016 |
|
Avelumab (Bavencio®) |
Monoclonal antibody (PD-L1) | Locally advanced or metastatic bladder cancer | May 2017 |
|
Durvalumab (Imfinzi®) |
Monoclonal antibody (PD-L1) | Locally advanced or metastatic bladder cancer | May 2017 |